Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Should Not Be a Barrier to Allogenic HSCT

Bone Marrow Transplant; ePub 2017 Sep 4; Modi, et al

Publish date:: September 17, 2017

Older age alone should not be considered a barrier to receiving allogeneic hematopoietic stem cell transplant (HSCT) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), according to a retrospective analysis involving 159 individuals.

Participants were aged ≥60 years with AML (n=103) or MDS (n=56) who underwent allogenic HSCT between 2005 and 2014. Investigators looked at nonrelapse mortality, relapse, relapse-free survival, and overall survival 1 year after transplant. Among the results:

Grade III-IV acute graft-vs-host disease (GVHD) occurred in 21% of patients; chronic GVHD occurred in 54%.
Nonrelapse mortality, relapse-free survival, relapse rate, and overall survival were 25%, 53%, 21%, and 56%, respectively.
High disease risk index was linked with poor relapse-free and overall survival, as well as higher relapse rate.
Non-thymoglobulin-based GVHD prophylaxis, higher comorbidity index, and MDS were linked with higher nonrelapse mortality.
Age did not adversely impact nonrelapse mortality, relapse, relapse-free survival, and overall survival.

Citation:

Modi D, Deol A, Kim S, et al. Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome. [Published online ahead of print September 4, 2017]. Bone Marrow Transplant. doi:10.1038/bmt.2017.182.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release